[New generation of androgen receptor antagonist in castration resistant prostate cancer]

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Context:

• Advanced prostate cancer often becomes resistant to androgen ablation therapy, progressing to castration-resistant prostate cancer (CRPC).
• Androgen Receptor (AR) signaling remains critical for CRPC growth, even in low androgen environments.
• Existing treatments like bicalutamide have limitations in managing advanced CRPC.

Purpose:

• To review novel androgen receptor (AR) antagonists developed for treating castration-resistant prostate cancer (CRPC).
• To highlight the mechanisms of action and efficacy of new agents compared to older therapies.
• To discuss the impact of these agents on the treatment landscape of advanced prostate cancer.

Summary:

• Novel AR antagonists, including enzalutamide and ARN-509, exhibit high affinity for AR.
• These agents effectively inhibit AR nuclear translocation and DNA binding, crucial for CRPC progression.
• Unlike bicalutamide, these newer drugs offer enhanced AR blockade.

Impact:

• These advanced AR antagonists represent a significant shift in CRPC treatment strategies.
• They offer promising outcomes and improved management for patients with advanced prostate cancer.
• The development of these agents underscores the importance of targeting AR signaling in overcoming treatment resistance.